Microbiotica raises $47.7 million Series C round led by British Business Bank

Microbiotica has raised $47.7 million (£35.7 million) in a Series C funding round to advance its clinical pipeline, according to transaction records indexed by deal tracking platform Fireround on October 18, 2026. The financing was supported by the British Business Bank alongside six other institutional venture capital investors.

The biotechnology company, which is headquartered in Cambridge, UK, develops live bacterial therapeutics derived from the human gut microbiome. Microbiotica will deploy the newly raised capital to support clinical trial development for its primary therapeutic pipelines in immuno-oncology and inflammatory bowel disease.

Clinical Development and Investor Backing

The Series C investment provides fresh funding for Microbiotica as it moves its therapeutic programs through clinical testing. By utilizing bacterial strains isolated from the human gut microbiome, the company aims to create targeted treatments for cancer and gut-related inflammatory conditions.

The British Business Bank led the financing, joined by six other institutional venture capital firms. Transaction details for the Series C round were formally indexed in venture tracking databases on October 18, 2026, confirming the full $47.7 million transaction value.

The investment in Microbiotica forms part of broader venture capital deployment into the UK life sciences sector. Institutional backers continue to allocate capital toward UK-based drug development platforms and clinical-stage biotechnology companies.

Broader Venture Funding Activity

Data published by Fireround shows sustained activity across global venture capital markets. In the 30 days leading up to October 19, 2026, startups announced 596 funding rounds representing $32 billion in total disclosed capital. Seed funding was the most common stage during this period, accounting for 163 individual rounds. The largest transaction in that 30-day window was a $3.4 billion convertible round raised by Nscale and led by Third Point Ventures.

Venture activity remained active in the middle of October, with startups securing $5.7 billion across 141 rounds in the seven days prior to October 19. Other biotechnology and health raises recorded during the same week included Pharmuna, which secured $5 million on October 18 through FasterCapital with Hesham Zreik as lead investor, and Flavii Therapeutics, which raised $949,000 in funding on October 17.

Additional UK and international transactions tracked during the week of October 16 included Unravel Health's $3.3 million round led by Conduit EIS Impact Fund, Round Group's $5.3 million seed round, and Elio Mortgage's $5.1 million pre-seed launch. Microbiotica remains based in Cambridge as it expands its clinical programs following the capital raise.